Dilate blood vessels

It has the effects of anti-platelet aggregation, dilating arterioles, improving microcirculation, activating blood circulation and removing blood stasis, and has the effect of disaggregating aggregated platelets

The contrast-producing substance in diatrizoate injection is a diatrizoate salt, in which tightly bound iodine absorbs X-rays.

1 Pharmacology The substance that produces the contrast effect in diatrizoate injection is a diatrizoate, in which the firmly bound iodine absorbs X-rays. 2 Toxicology Systemic toxicity Based on the results of acute toxicity studies, no risk of acute poisoning was found with the use of diatrizoate injection. Animal studies on systemic tolerance with repeated daily intravenous administration did not find any results that were unfavorable to the usually one-time diagnostic use in humans. Potential genotoxicity, carcinogenicity Studies on genotoxicity did not find diatrizoate to have a mutagenic effect in vivo or in vitro. Based on the above results, and taking into account the metabolic stability of diatrizoate and the one-time diagnostic use of diatrizoate injection, it is believed that diatrizoate injection has no carcinogenic risk to humans. Local tolerance and contact sensitization possibility Local tolerance studies did not show that diatrizoate injection had local adverse reactions to blood vessels, or mucous membranes or serosal membranes in the human body. Mild to moderate local intolerance reactions may occur if diatrizoate injection is accidentally injected into blood vessels or into other tissues.

The contrast-producing substance in diatrizoate injection is a diatrizoate salt, in which tightly bound iodine absorbs X-rays.

1 Pharmacology The substance that produces the contrast effect in diatrizoate injection is a diatrizoate, in which the firmly bound iodine absorbs X-rays. 2 Toxicology Systemic toxicity Based on the results of acute toxicity studies, no risk of acute poisoning was found with the use of diatrizoate injection. Animal studies on systemic tolerance with repeated daily intravenous administration did not find any results that were unfavorable to the usually one-time diagnostic use in humans. Potential genotoxicity, carcinogenicity Studies on genotoxicity did not find diatrizoate to have a mutagenic effect in vivo or in vitro. Based on the above results, and taking into account the metabolic stability of diatrizoate and the one-time diagnostic use of diatrizoate injection, it is believed that diatrizoate injection has no carcinogenic risk to humans. Local tolerance and contact sensitization possibility Local tolerance studies did not show that diatrizoate injection had local adverse reactions to blood vessels, or mucous membranes or serosal membranes in the human body. Mild to moderate local intolerance reactions may occur if diatrizoate injection is accidentally injected into blood vessels or into other tissues.

This product is a diagnostic drug. The sodium ion concentration of its 76% solution is about 136mmol/L, which is close to the concentration in plasma and has little effect on myocardial cell function. Sodium diatrizoate is an ionic monomer iodine contrast agent. Iodine can absorb a large amount of X-rays. After being injected into the body, it forms a density contrast with the surrounding tissues under X-rays and develops. When using the direct introduction method for contrast imaging, it can be directly injected into the blood vessels or other cavities to show the luminal morphology. When using the physiological absorption method for contrast imaging, the contrast agent injected into the blood vessels can enter the diseased tissue through the damaged vascular endothelium or the damaged blood-brain barrier to show the lesions. The urinary tract morphology can be displayed when excreted through the kidneys.